The role of microRNAs to understand sex-based differences in Alzheimer’s disease

Background Alzheimer’s disease (AD) is the most frequent cause of dementia and its incidence is expected to rise as the life expectancy of the population increases. Sex-based differences in AD development have been described, although there are still uncertainties on the role of biological sex in molecular mechanisms of the disease. The study of sex-specific expression profiles of regulatory elements, such as microRNAs (miRNAs), could contribute to a more accurate diagnosis and treatment of the disease. Methods We conducted a systematic review identifying five studies of microRNA expression in AD that incorporated the biological sex of the samples published in the Gene Expression Omnibus (GEO) repository. Differential expression analyses were performed for each study, considering both disease and biological sex of patients. Subsequently, results were integrated with a meta-analysis methodology. Finally, functional enrichment of the meta-analyses results was performed to establish an association between altered miRNA expression and relevant terms of the Gene Ontology (GO). Results Meta-analyses of miRNAs expression in blood samples revealed 16 and 22 miRNAs altered in females and males, respectively. Moreover, 9 miRNAs were commonly overexpressed in both sexes, unveiling common miRNAs dysregulation profiles. In contrast, functional enrichment revealed sex-differences in biological processes altered. In males, most of the affected processes were related to ubiquitination, regulation of different kinase activities and apoptotic processes; but in females were linked to RNA splicing and translation. Meta-analyses of brain samples also revealed some alterations in miRNAs expression (6 in females and 4 in males). The unique miRNA altered in both sexes (miR-767-5p) was underexpressed in both males and females. Nonetheless, the functional enrichment analysis did not reveal any affected biological process. Conclusions Sex-specific meta-analyses allowed for the detection of differentially expressed miRNAs in females and males. Identification of deregulated miRNAs highlighted the relevance of the sex information in biomedical data. Further studies centered on miRNA regulation should meet criteria for comparability and standardization of information.

[1]  Marta R. Hidalgo,et al.  A deep transcriptome meta-analysis reveals sex differences in multiple sclerosis , 2023, Neurobiology of Disease.

[2]  B. F. Mogharbel,et al.  State of the Art of microRNAs Signatures as Biomarkers and Therapeutic Targets in Parkinson’s and Alzheimer’s Diseases: A Systematic Review and Meta-Analysis , 2023, Biomedicines.

[3]  H. Changotra,et al.  Dysregulated miRNAs in Progression and Pathogenesis of Alzheimer’s Disease , 2022, Molecular Neurobiology.

[4]  A. Koyanagi,et al.  Differential expression of MicroRNAs in Alzheimer’s disease: a systematic review and meta-analysis , 2022, Molecular Psychiatry.

[5]  Bin Wang,et al.  CircAXL Knockdown Alleviates Aβ1-42-Induced Neurotoxicity in Alzheimer’s Disease via Repressing PDE4A by Releasing miR-1306-5p , 2022, Neurochemical Research.

[6]  W. Liang,et al.  Inhibiting microRNA-142–5p improves learning and memory in Alzheimer’s disease rats via targeted regulation of the PTPN1-mediated Akt pathway , 2022, Brain Research Bulletin.

[7]  In Soo Ryu,et al.  miRNAs as Therapeutic Tools in Alzheimer’s Disease , 2021, International journal of molecular sciences.

[8]  D. Galimberti,et al.  Pharmacological and Epigenetic Regulators of NLRP3 Inflammasome Activation in Alzheimer’s Disease , 2021, Pharmaceuticals.

[9]  Marta R. Hidalgo,et al.  Unveiling sex-based differences in Parkinson's disease: a comprehensive meta-analysis of transcriptomic studies , 2021, Biology of Sex Differences.

[10]  K. Ozaki,et al.  Dementia subtype prediction models constructed by penalized regression methods for multiclass classification using serum microRNA expression data , 2021, Scientific Reports.

[11]  A. Dhawan Extracellular miRNA biomarkers in neurologic disease: is cerebrospinal fluid helpful? , 2021, Biomarkers in medicine.

[12]  Li-Li Ji,et al.  miR-142 downregulation alleviates the impairment of spatial learning and memory, reduces the level of apoptosis, and upregulates the expression of pCaMKII and BAI3 in the hippocampus of APP/PS1 transgenic mice , 2021, Behavioural Brain Research.

[13]  T. Strovas,et al.  Pathological tau drives ectopic nuclear speckle scaffold protein SRRM2 accumulation in neuron cytoplasm in Alzheimer’s disease , 2021, Acta Neuropathologica Communications.

[14]  A. Carè,et al.  A Sex Perspective in Neurodegenerative Diseases: microRNAs as Possible Peripheral Biomarkers , 2021, International journal of molecular sciences.

[15]  L. Tan,et al.  The Epidemiology of Alzheimer’s Disease Modifiable Risk Factors and Prevention , 2021, The Journal of Prevention of Alzheimer's Disease.

[16]  Jacob I. Ayers,et al.  Tau aggregates are RNA-protein assemblies that mislocalize multiple nuclear speckle components , 2021, Neuron.

[17]  Marta R. Hidalgo,et al.  Hepatic steatosis and steatohepatitis: a functional meta-analysis of sex-based differences in transcriptomic studies , 2021, Biology of sex differences.

[18]  Bin Zhang,et al.  Sex Differences in Alzheimer’s Disease: Insights From the Multiomics Landscape , 2021, Biological Psychiatry.

[19]  Anushya Muruganujan,et al.  The Gene Ontology resource: enriching a GOld mine , 2020, Nucleic Acids Res..

[20]  Christopher J. Tonkin,et al.  TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS , 2020, Cell.

[21]  C. Reitz,et al.  Late-onset vs nonmendelian early-onset Alzheimer disease , 2020, Neurology: Genetics.

[22]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.

[23]  Z. Hojati,et al.  The Highlighted Roles of Metabolic and Cellular Response to Stress Pathways Engaged in Circulating hsa-miR-494-3p and hsa-miR-661 in Alzheimer’s Disease , 2020, Iranian biomedical journal.

[24]  Marta R. Hidalgo,et al.  Functional Signatures in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Sex-Based Differences in Transcriptomic Studies , 2020, medRxiv.

[25]  Zhi-Yong Wang,et al.  MicroRNAs in Alzheimer’s Disease: Function and Potential Applications as Diagnostic Biomarkers , 2020, Frontiers in Molecular Neuroscience.

[26]  Marta R. Hidalgo,et al.  Unveiling Sex-Based Differences in the Effects of Alcohol Abuse: A Comprehensive Functional Meta-Analysis of Transcriptomic Studies , 2020, bioRxiv.

[27]  Keith A. Johnson,et al.  Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline , 2020, Annals of neurology.

[28]  K. Barve,et al.  Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease , 2020, Current neuropharmacology.

[29]  C. Gravholt,et al.  What microRNAs could tell us about the human X chromosome , 2020, Cellular and Molecular Life Sciences.

[30]  N. Zhang,et al.  Berberine attenuates Aβ42-induced neuronal damage through regulating circHDAC9/miR-142-5p axis in human neuronal cells. , 2020, Life sciences.

[31]  Zhu Chen,et al.  Profile of Pathogenic Proteins and MicroRNAs in Plasma-derived Extracellular Vesicles in Alzheimer’s Disease: A Pilot Study , 2020, Neuroscience.

[32]  R. Perneczky,et al.  Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid , 2019, Alzheimer's & Dementia.

[33]  Nick C Fox,et al.  Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.

[34]  Nicholas M. Wragg,et al.  Systematic Review of miRNA as Biomarkers in Alzheimer’s Disease , 2019, Molecular Neurobiology.

[35]  Ana Kozomara,et al.  miRBase: from microRNA sequences to function , 2018, Nucleic Acids Res..

[36]  Nuno A. Fonseca,et al.  ArrayExpress update – from bulk to single-cell expression data , 2018, Nucleic Acids Res..

[37]  S. Aoki,et al.  The intellectual disability gene PQBP1 rescues Alzheimer’s disease pathology , 2018, Molecular Psychiatry.

[38]  Ketan S. Patil,et al.  Cellular Proteostasis in Neurodegeneration , 2018, Molecular Neurobiology.

[39]  C. Peng,et al.  Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation , 2018, Front. Endocrinol..

[40]  M. Mesulam,et al.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. , 2018, Brain : a journal of neurology.

[41]  W. Noble,et al.  A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies , 2018, Acta Neuropathologica Communications.

[42]  L. Rajendran,et al.  Microglia-Mediated Synapse Loss in Alzheimer's Disease , 2018, The Journal of Neuroscience.

[43]  A. Carè,et al.  Sex disparity in cancer: roles of microRNAs and related functional players , 2018, Cell Death & Differentiation.

[44]  L. Milanesi,et al.  The nuclear receptor ERβ engages AGO2 in regulation of gene transcription, RNA splicing and RISC loading , 2017, Genome Biology.

[45]  M. Mendez Early-Onset Alzheimer Disease. , 2017, Neurologic clinics.

[46]  K. Sandberg,et al.  How to study the impact of sex and gender in medical research: a review of resources , 2016, Biology of Sex Differences.

[47]  Ru-jing Ren,et al.  Diagnostic Value of microRNA for Alzheimer’s Disease: A Systematic Review and Meta-Analysis , 2016, Front. Aging Neurosci..

[48]  Russell Bowler,et al.  The multiMiR R package and database: integration of microRNA–target interactions along with their disease and drug associations , 2014, Nucleic acids research.

[49]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[50]  G. Barry Integrating the roles of long and small non-coding RNA in brain function and disease , 2014, Molecular Psychiatry.

[51]  Aikaterini S. Papadopoulou,et al.  Alteration of the microRNA network during the progression of Alzheimer's disease , 2013, EMBO molecular medicine.

[52]  Sabine C. Mueller,et al.  A blood based 12-miRNA signature of Alzheimer disease patients , 2013, Genome Biology.

[53]  Stefan L Ameres,et al.  Diversifying microRNA sequence and function , 2013, Nature Reviews Molecular Cell Biology.

[54]  S. Hauser Harrison's Neurology in Clinical Medicine , 2013 .

[55]  Sean R. Davis,et al.  NCBI GEO: archive for functional genomics data sets—update , 2012, Nucleic Acids Res..

[56]  T. Gale,et al.  Greater cognitive deterioration in women than men with Alzheimer's disease: A meta analysis , 2012, Journal of clinical and experimental neuropsychology.

[57]  Wolfgang Viechtbauer,et al.  Conducting Meta-Analyses in R with the metafor Package , 2010 .

[58]  Michael W. Weiner,et al.  Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans , 2010, Neurobiology of Aging.

[59]  J. Dopazo,et al.  Multidimensional Gene Set Analysis of Genomic Data , 2010, PloS one.

[60]  Juan Nunez-Iglesias,et al.  Joint Genome-Wide Profiling of miRNA and mRNA Expression in Alzheimer's Disease Cortex Reveals Altered miRNA Regulation , 2010, PloS one.

[61]  E. Birney,et al.  Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt , 2009, Nature Protocols.

[62]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[63]  T. Gale,et al.  Sex differences in Alzheimer's disease , 2018, Current opinion in psychiatry.

[64]  M. Robinson,et al.  Recent Progress in Alzheimer's Disease Research, Part 2: Genetics and Epidemiology. , 2018, Journal of Alzheimer's disease : JAD.

[65]  W. Rocca Time, Sex, Gender, History, and Dementia. , 2017, Alzheimer disease and associated disorders.

[66]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[67]  A. Andreadis Misregulation of tau alternative splicing in neurodegeneration and dementia. , 2006, Progress in molecular and subcellular biology.

[68]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .